Table 1.
Phenotype definitions: | Data domain criteria | |||||||
---|---|---|---|---|---|---|---|---|
ICD-9-CM 250.xx | ICD-9-CM 250.x0 and 250.x2 (excludes type 1 specific codes) | Expanded ICD-9-CM Codes (249.xx, 357.2, 362.0x, 366.41) | HbA1c | Fasting glucose | Random glucose | Abnormal OGTT | Diabetes-associated medications* | |
ICD-9-CM 250.xx | ||||||||
CMS CCW | ||||||||
NYC A1c Registry | ||||||||
Diabetes-associated medications | ||||||||
DDC | ||||||||
SUPREME-DM | ||||||||
eMERGE† |
*Medications vary by phenotype definition and are listed for each in the supplementary appendix (available online only).
†The eMERGE phenotype definition consists of five case scenarios with varying combinations of criteria. Any instance of type 1 specific codes (ie, 250.x1, 250.x3) results in the exclusion of the patient.
=Sole criteria.
=Optional criteria, one of many.
=Distinction made between inpatient and outpatient context.
= Distinction made for multiple instances and/or time points.
CMS CCW, Centers for Medicare and Medicaid Services Chronic Condition Data Warehouse; DDC, Durham Diabetes Coalition; eMERGE, electronic medical records and genomics; HbA1c, hemoglobin A1c; ICD-9-CM, International Classification of Disease, revision 9, clinical modification; NYC, New York City; OGTT, oral glucose tolerance test; SUPREME-DM, Surveillance, Prevention, and Management of Diabetes Mellitus.